← Back to Search

Anti-mitotic Agent

Drug Resistance Testing for Breast Cancer

Phase 2

Waitlist Available

Research Sponsored by Oncotech

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Bidimensionally measurable disease with at least one diameter greater than 1 cm documented on x-ray or photograph, or a palpable lesion

Metastatic breast cancer that is accessible for biopsy or aspiration

Timeline

Screening 3 weeks

Treatment Varies

Follow Up up to 5 years

Awards & highlights

Study Summary

This trial is testing a way to measure drug resistance to paclitaxel in patients with metastatic breast cancer to see if it is reliable.

Who is the study for?

This trial is for individuals with metastatic breast cancer that can be measured and has at least one area larger than 1 cm. Participants must have a tumor accessible for biopsy or aspiration. It's not open to those with brain metastases or carcinomatous meningitis.Check my eligibility

What is being tested?

The study is testing the reliability of a test that measures resistance to the chemotherapy drug paclitaxel in patients with metastatic breast cancer. This is a Phase II trial focused on how tumors respond to treatment.See study design

What are the potential side effects?

While specific side effects are not listed, common ones from chemotherapy like paclitaxel may include nausea, hair loss, fatigue, increased risk of infection, and numbness in fingers or toes.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I have a tumor that is larger than 1 cm or can be felt.

Select...

My metastatic breast cancer can be biopsied.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ up to 5 years

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~up to 5 years

This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

0 / 2Eligibility criteria met

Find a Location

Who is running the clinical trial?

OncotechLead Sponsor

1 Previous Clinical Trials

1,100 Total Patients Enrolled

Rita S. Mehta, MDStudy ChairOncotech

1 Previous Clinical Trials

695 Total Patients Enrolled

1 Trials studying Breast Cancer

695 Patients Enrolled for Breast Cancer

Media Library

Paclitaxel (Anti-mitotic Agent) Clinical Trial Eligibility Overview. Trial Name: NCT00003253 — Phase 2

Breast Cancer Clinical Trial 2023: Paclitaxel Highlights & Side Effects. Trial Name: NCT00003253 — Phase 2

Paclitaxel (Anti-mitotic Agent) 2023 Treatment Timeline for Medical Study. Trial Name: NCT00003253 — Phase 2

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is the procedure associated with any adverse side effects for patients?

"There is some safety evidence from a Phase 2 trial, so we've estimated this treatment to have a risk rating of 2. Unfortunately there are no current efficacy data points for us to evaluate."

Answered by AI

How many facilities are offering this clinical investigation?

"Nine medical institutions are in the process of enrolling participants, highlighted by USC/Norris Comprehensive Cancer Center and Hospital in Los Angeles, Chao Family Comprehensive Cancer Center in Orange, and Palmetto Hematology/Oncology Associates in Spartanburg. In total there are 12 sites taking part."

Answered by AI

Is enrollment for this experiment open at the moment?

"According to clinicaltrials.gov, this medical trial is no longer recruiting participants; the study was initially posted in July 1997 and last edited in December 2013. Nonetheless, over two thousand six hundred other trials are presently looking for patients to join them."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Evaluation of Drug Resistance in Patients With Metastatic Breast Cancer

1997. "Evaluation of Drug Resistance in Patients With Metastatic Breast Cancer". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT00003253.

All > Breast Cancer Hawaii > Breast